Structure Therapeutics Inc. is updating its disclosures regarding the sales of GLP-1R and GLP-1R/GIPR peptides approved for type 2 diabetes and obesity, and supplementing its risk factors.
AI Assistant
STRUCTURE THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.